Table 2: Geometric Mean Titers (GMT) and Geometric Mean Fold Rises (GMFR) in Serum Antibodies

Table 2: Geometric mean titers (GMT) and geometric mean fold rises (GMFR) in serum antibodies

Virus / Cohort 1 (104 TCID50) / Cohort 2 (105 TCID50) / Cohort 3 (106 TCID50)
MEDI-534
N=19 / Placebo
N=21 / MEDI-534
N=21 / Placebo
N=19 / MEDI-534
N=20 / Placebo
N=20
RSV* / Day 0
GMT (95% CI)† / 42.00 (25.6, 69.8) / 49.19 (32.3, 74.9) / 68.42 (47.3, 95.7) / 50.86 (34.8, 74.0) / 52.99 (33.7, 84.5) / 52.93 (32.9, 83.2)
Day 28-35
GMT (95% CI) / 40.75 (25.7, 66.9) / 42.86 (29.5, 62.8) / 61.55 (43.3, 88.3) / 48.04 (32.2, 70.7) / 66.92 (41.4, 109.2) / 53.27 (32.8, 85.8)
GMFR‡ / 0.93 (0.7, 1.5) / 0.87 (0.7, 1.0) / 0.93 (0.8, 1.1) / 0.94 (0.8, 1.1) / 1.26 (0.9, 2.1) / 1.02 (0.9, 1.2)
hPIV3§ / Day 0
GMT (95% CI) / 114.04 (66.5, 198.3) / 89.03 (54.3, 146.1) / 112.17 (68.4, 178.1) / 112.17 (68.4, 178.1) / 137.19 (76.1, 247.3) / 148.11 (93.9, 246.3)
Day 28-35
GMT (95% CI) / 118.99 (79.7, 184.4) / 83.34 (49.1, 136.7) / 103.97 (66.3, 157.6) / 103.97 (66.3, 157.6) / 123.64 (71.0, 207.9) / 187.40 (115.4, 304.4)
GMFR / 1.08 (0.9, 1.3) / 0.94 (0.8, 1.0) / 1.04 (0.9, 1.2) / 1.04 (0.9, 1.2) / 0.90 (0.8, 1.1) / 1.29 (1.0, 1.8)
* neutralization assay; results are the mean of replicate 1 and replicate 2; § hemagglutination inhibition (HAI) assay; † for titer reported as <20, a value of 10 was assigned when computing GMT; ‡ GMFR is the geometric mean of the ratios of post-dose antibody to the pre-dose antibody